



## SCIENTIFIC PROGRAM

### Thursday, March 22, 2007

**15:00-16:00 PRE-CONGRESS SYMPOSIUM  
INNOVATIVE APPROACHES IN  
WOMEN'S HEALTH FOR DAILY  
PRACTICE**

**Sponsored by Bayer Schering Pharma**

*Chairman:* **J. Calaf, Spain**

- Introduction on BSP  
**P. Smits, Germany**
- Yasminelle® - a new low dose oral contraceptive designed for the needs of today's women  
**M. Sillem, Germany**

- Superior efficacy of Mirena® in contraception and menorrhagia  
**S. Haimovich, Spain**
- Benefits of Angeliq®'s blood pressure effects, in daily practice  
**H. Depypere, Germany**

**18:30 WELCOME RECEPTION**

**Sponsored in part by an unrestricted grant from Wyeth Pharmaceuticals**

### Friday, March 23, 2007

**GYNECOLOGY/ENDOSCOPY/MENOPAUSE AND FAMILY PLANNING**

**HALL A**

**08:30-10:00 SURGICAL APPROACH TO  
HYSTERECTOMY**

*Capsule:* *Patient's interest is to undergo hysterectomy by masters of all techniques*

*Chairpersons:* **V. Gomel, Canada**  
**E. Zupi, Italy**  
**L.R. Glazerman, USA**

**08:30-09:30 DEBATE  
What is the preferred route for  
hysterectomy?**

**Proposition:** Most uteri can be removed by laparoscopy!

**J. Donnez, Belgium**

**Opposition:** Most uteri can be removed vaginally!

**J-P. Lucot, France**

**09:30-10:00** Physicians should familiarize themselves with simpler methods for vaginal hysterectomy!

**M. Stark, Germany**

**10:00-10:30** *Coffee Break*

**10:30-12:00 THE PREMENSTRUAL  
SYMPTOMATOLOGY FROM  
DIFFERENT ANGLES**

**Sponsored by an unrestricted grant from Bayer Schering Pharma**

*Chairperson:* **A.R. Genazzani, Italy**

**10:30-10:35** Introduction  
**A.R. Genazzani, Italy**

**10:35-11:00** Pathophysiology, definition of the disease, and treatment options

**N. Panay, UK**

**11:00-11:25** Premenstrual syndrome symptoms - cross-cultural and epidemiological studies

**L. Dennerstein, Australia**

**11:25-11:45** PMS in Spain

**J. Calaf, Spain**

**11:45-12:15 MANAGEMENT OF  
CARDIOVASCULAR RISK IN THE  
PERIMENOPAUSAL WOMAN: A  
CONSENSUS STATEMENT OF  
EUROPEAN CARDIOLOGISTS AND  
GYNAECOLOGISTS**

*Chairperson:* **A. Genazzani, Italy**

*Speaker:* **P. Collins, UK**

**12:15-12:30 Discussion**

**12:30-13:30** *Lunch Break*

**13:30-15:30 HPV VACCINATION**

**Sponsored by an unrestricted grant from Sanofi Pasteur MSD**

*Capsule:* *What can be expected from this innovative development in prevention of cervical cancer and how can it impact our current management?*

*Chairpersons:* **S. Dexeus, Spain**

**R.G. Moore, USA**



## SCIENTIFIC PROGRAM

(CONTINUED)

Friday, March 23, 2007

GYNECOLOGY/ENDOSCOPY/MENOPAUSE AND FAMILY PLANNING

HALL A

- |   |   |
|---|---|
| <p><b>13:30-14:00</b> Epidemiology of HPV related disease of the lower genital tract: A European perspective<br/><b>X. Bosch, Spain</b></p> <p><b>14:00-14:30</b> Burden of HPV related disease of the lower genital tract in Germany<br/><b>P. Hillemanns, Germany</b></p> <p><b>14:30-15:00</b> Perspectives on the clinical management of HPV related disease of the lower genital tract<br/><b>P. Hillemanns, Germany</b></p> <p><b>15:00-15:30</b> The promise of HPV vaccination<br/><b>X. Bosch, Spain</b></p> <hr/> <p><b>15:30-16:00</b> <i>Coffee Break</i></p> | <p><b>16:00-17:30</b> <b>HT IN MENOPAUSE</b><br/><b>Capsule:</b> <i>Can we revert to our old habits of HT prescription?</i><br/><b>Chairperson:</b> <b>S. Skouby, Belgium</b><br/><b>R. Lobo, USA</b></p> <p><b>16:00-16:30</b> Who are the appropriate candidates for HT/ET after WHI?<br/><b>R. Lobo, USA</b></p> <p><b>16:30-17:30</b> <b>DEBATE</b><br/><b>This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis</b><br/><b>For: TBA</b><br/><b>Against: J. Compston, UK</b></p> |
|---|---|

INFERTILITY & ART

HALL B

- |   |   |
|---|---|
| <p><b>08:30-10:00</b> <b>PGD - CLINICAL AND ETHICAL IMPLICATIONS</b><br/><b>Capsule:</b> <i>Is PGD still an experimental procedure that needs clinical and ethical refinement?</i><br/><b>Chairpersons:</b> <b>R. Frydman, France</b><br/><b>K. Diedrich, Germany</b><br/><b>F. Vidal, Spain</b></p> <p><b>08:30-09:30</b> <b>DEBATE</b><br/><b>What should be tested and should these tests be universally used?</b></p> <ul style="list-style-type: none"> <li>• Should we test the first polar body or the embryo?</li> </ul> <p><b>L. Gianaroli, Italy</b></p> <ul style="list-style-type: none"> <li>• The polar body and embryo should be tested sequentially!</li> </ul> <p><b>Y. Verlinsky, USA</b></p> <p><b>09:30-10:00</b> <b>Discussion</b><br/><b>PGD should be offered to all patients!</b><br/><b>Yes: Y. Verlinsky, USA</b><br/><b>No: N. Gleicher, USA</b><br/><b>Maybe: L. Gianaroli, Italy</b></p> <hr/> <p><b>10:00 - 10:30</b> <i>Coffee Break</i></p> | <p><b>10:30 - 12:30</b> <b>OVARIAN STIMULATION</b><br/><b>Sponsored by an unrestricted grant from Institute Biochimique S.A.</b><br/><b>Capsule:</b> <i>Ovarian stimulation is the most crucial step in IVF, yet no agreement consensus exists on basic issues</i><br/><b>Chairpersons:</b> <b>P.N. Barri, Spain</b><br/><b>N. Gleicher, USA</b><br/><b>S. Mashiach, Israel</b></p> <p><b>10:30-11:30</b> <b>DEBATE</b><br/><b>Do we need to add LH for ovarian stimulation?</b><br/><b>Yes:</b> We do need LH/hCG and administration regimens could be critical<br/><b>M. Filicori, Italy</b><br/><b>No:</b> We do not need LH: in fact, FSH alone is most beneficial<br/><b>S. Daya, Canada</b></p> <p><b>11:30-12:00</b> Agonist or antagonists? What is preferable? Agonist!<br/><b>A. Pellicer, Spain</b></p> <p><b>12:00-12:30</b> Agonist or Antagonist? Answer by meta-analysis and the patients<br/><b>K. Diedrich, Germany</b></p> <hr/> <p><b>12:30 - 13:30</b> <i>Lunch Break</i></p> |
|---|---|



## SCIENTIFIC PROGRAM

(CONTINUED)

Friday, March 23, 2007

### INFERTILITY & ART

HALL B

#### 13:30 - 15:30 IVM SYMPOSIUM

Sponsored by an unrestricted grant from MediCult Espania S.L.

**Capsule:** *With the increasing success of IVF-will IVM ever replace standard IVF*

**Chairpersons:** **Y. Verlinsky, USA**  
**B. Dal Canto, Italy**  
**B. Coroleu-Lletget, Spain**

**13:30-14:00** Clinical protocols in In Vitro Maturation-clinical consensus after IVM expert workshop, MediCult Denmark  
**R. Fadini-Monza, Italy**

**14:00-14:30** Can we agree on a universal protocol for IVM? - laboratory consideration  
**B. Dal Canto-Monza, Italy**

**14:30-15:00** Experience with IVM. Patients' point of view  
**F. Martinez, Spain**

**15:00-15:30** The Japanese approach to IVM  
**A. Fukuda, Japan**

**15:30 - 16:00** *Coffee Break*

#### 16:00 - 17:30 STEM CELLS

**Capsule:** *Stem cells are emerging as a future tool for therapy: What are today's options?*

**Chairpersons:** **R.F. Casper, Canada**  
**A. Veiga, Spain**  
**M. Boada, Spain**

**16:00-16:30** Human embryonic stem cells today - research or therapeutic tool?  
**A. Veiga, Spain**

**16:30-17:00** Cord blood stem cells - what can be expected?  
**J. García, Spain**

**17:00-17:30** The future of adult and embryonic stem cells  
**R.F. Casper, Canada**

### FETO-MATERNAL MEDICINE

HALL C

#### 08:15-10:00 3D ULTRASOUND, THE FUTURE IS HERE!

Sponsored by an unrestricted grant from Medison Europe BV

**Capsule:** *Will 3D preserve the role of ultrasound in obstetrics?*

**Chairpersons:** **I. Shapiro, Israel**  
**P.N. Barri Soldevila, Spain**  
**K. Kalache, UK**

**08:15-08:35** New modalities for imaging the fetal central nervous system 3D & 3DXI  
**J. Perez-Pedregosa, Spain**

**08:35-08:55** 3D ultrasound assessment of fetal lung tumors  
**W. Sepulveda, Chile**

**08:55-09:15** 3D ultrasound: Gimmick or breakthrough?  
**I. Shapiro, Israel**

**09:15-09:40** Horses for courses – which application for which fetal anomaly?  
*Live Demonstration*  
**K. Kalache, UK**

**09:40-10:00** Pitfalls and artifacts in three-dimensional ultrasound  
**I. Shapiro, Israel**

**10:00-10:30** *Coffee Break*

#### 10:30-12:30 SCREENING FOR ANOMALIES

**Capsule:** *Can we do without some of the screening tests for Down's Syndrome?*

**Chairpersons:** **Y. Ville, France**  
**J. Gardosi, UK**  
**T.T. Hsieh, Taiwan**

#### DEBATE

**First trimester screening - All you need is a U/S machine?**

**10:30-11:00** First trimester U/S screening is a must  
**K. Nicolaides, UK**

**11:00-11:30** U/S is great but biochemical screening is more important!  
**H.S. Cuckle, UK**

**11:30-12:30** New avenues in U/S screening  
**K. Nicolaides, UK**  
Noninvasive prenatal diagnosis test from maternal blood  
**R. Dhallan, USA**

**12:30-13:30** *Lunch Break*

#### 13:30-15:30 MANAGEMENT OF TWINS

**Capsule:** *Multiple pregnancies multiple problems?*

**Chairpersons:** **K. Nicolaides, UK**  
**I. Shapiro, Israel**  
**W.W. Sumpaico, Philippines**



## SCIENTIFIC PROGRAM

(CONTINUED)

Friday, March 23, 2007

FETO-MATERNAL MEDICINE

HALL C

- 13:30-14:30 DEBATE**  
**Should we routinely offer to reduce twins to singleton?**  
**Yes:** The results of twins are consistently lower than singleton  
**I. Blickstein, Israel**  
**No:** The risk of reducing is too high, twins should be left intact!  
**Y. Ville, France**
- 14:30-15:00** Fetal growth in twins  
**J. Gardosi, UK**
- 15:00-15:30** Treatment of twin-to-twin transfusion syndrome: The end of a longstanding misunderstanding?  
**Y. Ville, France**
- 15:30-16:00** *Coffee Break*
- 16:00-17:30 FROM CONCEPTION TO DELIVERY: ADDRESSING THE CHALLENGES OF TREATMENT**  
**Sponsored by an unrestricted grant from Ferring Pharmaceuticals**  
*Chairperson:* **L. Cabero-Roura, Spain**
- 16:00-16:30** Addressing the outcome challenge: The value of LH in ART  
**E. Bosch, Spain**
- 16:30-17:00** Tocolysis: Is it time to challenge current practice?  
**G.C. Di Renzo, Italy**
- 17:00-17:30** The challenge of post partum haemorrhage: How can prevention be improved?  
**M. Boucher, Canada**





## SCIENTIFIC PROGRAM

(CONTINUED)

**Saturday, March 24, 2007**

**GYNECOLOGY/ENDOSCOPY/MENOPAUSE AND FAMILY PLANNING**

**HALL A**

**08:00-10:00 HORMONAL CONTRACEPTION**

**Capsule:** *Are we expanding the choice of hormonal contraception or adding confusion?*

**Chairpersons:** **S. Skouby, Denmark**  
**N-O. Sjoberg, Sweden**  
**M. Sillem, Germany**

**08:00-08:30** Progesterone only pills - first or last choice?

**R.E. Nappi, Italy**

**08:30-09:00** Hormonal contraception: Roots and development

**S. Skouby, Denmark**

**09:00-09:30** Vaginal contraception - advantages and disadvantages?

**D.S. Seidman, Israel**

**09:30-10:00** Extended use of hormonal contraception - how long can we go?

**J. Calaf, Spain**

**10:00-10:30** *Coffee Break*

**10:30-12:30 HT FOR THE PREVENTION OF CVD**

**Capsule:** *WHI results indicating a deleterious effect of HT on the CVS remains controversial!*

**Chairpersons:** **R. Lobo, USA**  
**N. Siseles, Argentina**  
**J. Calaf, Spain**

**10:30-11:00** HT and CVD: Can the starter effect be eliminated?

**J.C. Stevenson, UK**

**11:00-11:30** HT and CVD: How to define the therapeutic window?

**S. Skouby, Denmark**

**11:30-12:00** HT: Is the low-dose concept appropriate for all organ systems?

**S. Rozenberg, Belgium**

**12:00-12:30** Breast cancer - does the choice of progestogen influence the risk of breast cancer?

**A.R. Genazzani, Italy**

**12:30-13:30** *Lunch Break*

**13:30-15:30 LAPAROSCOPY – HYSTERECTOMY AND COMPLICATIONS**

**Sponsored in part by an unrestricted grant from KARL STORZ GmbH & Co. KG**

**Capsule:** *Laparoscopy is a potent operative tool, but the debate over safety and indications is still ongoing*

**Chairpersons:** **V. Gomel, Canada**  
**C. Goldchmit, Israel**  
**P. Viscasillas, Spain**

**13:30-14:00** Robots and simulators - do they have a role in endoscopic surgery?

**F. Nezhat, USA**

**14:00-14:30** LAVH – a procedure that has come and gone?

**L. R. Glazerman, USA**

**14:30-15:00** The pros and cons of laparoscopic myomectomy

**J. Donnez, Belgium**

**15:00-15:30** Laparoscopy during pregnancy including cerclage

**F. Nezhat, USA**

**15:30-16:00** *Coffee Break*

**16:00-17:30 HRT AND CORONARY DISEASE PREVENTION**

**Capsule:** *Do we have enough hard data to oppose the WHI conclusion on heart disease?*

**Chairpersons:** **A.R. Genazzani, Italy**  
**S. Rozenberg, Belgium**  
**S. Palacios, Spain**

**16:00-16:30** The metabolic basis for CHD prevention with HRT

**J.C. Stevenson, UK**

**16:30-17:30 DEBATE**

**This house believes that HRT will only prevent CHD in younger women without an existing disease**

**Against: P. Collins, UK**

**For: S. Rozenberg, Belgium**

**17:30-19:00 FREE COMMUNICATIONS**

**Chairpersons:** **S. Rozenberg, Belgium**  
**S. Palacios, Spain**

**17:30-17:42** Different treatment options for dysfunctional uterine bleedings

**G.M. Graziotin, Brazil**



## SCIENTIFIC PROGRAM

(CONTINUED)

**Saturday, March 24, 2007**

**GYNECOLOGY/ENDOSCOPY/MENOPAUSE AND FAMILY PLANNING**

**HALL A**

- |   |   |
|---|---|
| <p><b>17:42-17:54</b> Hysteroscopic sterilisation using an intratubal device<br/><b>P.F.C. Rocha, Portugal</b></p> <p><b>17:54-18:06</b> Laparoscopic approach of mild endometriosis: excision or coagulation?<br/><b>B. Alexandru, Romania</b></p> <p><b>18:06-18:18</b> Adolescent gynecology: what can be offered?<br/><b>O. Kadayifci, Turkey</b></p> <p><b>18:18-18:30</b> A study of the knowledge in Rasht women toward osteoporosis<br/><b>K.S. Seyam, Iran</b></p> | <p><b>18:30-18:42</b> Continuation and reasons for discontinuation of depot medroxyprogesterone acetate (dmpa) among women referring to ardebil health clinics 2005<br/><b>A. Mardi, Iran</b></p> <p><b>18:42-18:54</b> Efficiency of cytology and colposcopy in the diagnosis of cervical lesions from the human papiloma virus<br/><b>G. Vega-Malagon, Mexico</b></p> <p><b>18:54-19:00</b> Q&amp;A</p> |
|---|---|

**INFERTILITY & ART**

**HALL B**

- |   |   |
|---|---|
| <p><b>08:00-10:00</b> <b>PCOS</b><br/><i>Capsule:</i> Are we coming closer to understanding and treating this enigmatic endocrinopathy?<br/><i>Chairpersons:</i> <b>M. Filicori, Italy</b><br/><b>A. Weissman, Israel</b><br/><b>R. Tur, Spain</b></p> <p><b>08:00-09:00</b> <b>DEBATE</b><br/><b>Metformin for all PCOS patients?</b><br/><b>Proposition:</b> Metformin should be the first line of therapy in PCOS patients!<br/><b>H.F. Escobar-Morreale, Spain</b><br/><b>Opposition:</b> No advantage to the use of Metformin for all PCOS patients!<br/><b>S. Daya, Canada</b></p> <p><b>09:00-09:30</b> Androgen excess component in the diagnosis of PCOS<br/><b>R. Lobo, USA</b></p> <p><b>09:30-10:00</b> Revisiting of the Rotterdam criteria for the definition of PCOS<br/><b>A.M. Fulghesu, Italy</b></p> <p><b>10:00-10:30</b> <i>Coffee Break</i></p> <p><b>10:30-12:30</b> <b>IVF SUCCESS RATE – CAN WE DO BETTER?</b><br/><b>Supported by an unrestricted grant from Organon International</b><br/><i>Capsule:</i> Changing Treatment Paradigm – is it associated with increasing success?<br/><i>Chairpersons:</i> <b>P.N. Barri, Spain</b><br/><b>L. Gianaroli, Italy</b></p> | <p><b>10:30-11:00</b> How can we improve stimulation protocols? Can we offer more?<br/><b>E. Heijnen, The Netherlands</b></p> <p><b>11:00-11:30</b> How can we improve implantation? Is it embryo quality, endometrial receptivity or technical issues of the transfer?<br/><b>J.A. García-Velasco, Spain</b></p> <p><b>11:30-12:00</b> How can we improve luteal phase support? What to use, when to start and for how long?<br/><b>G. Griesinger, Germany</b><br/><i>Discussion</i></p> <p><b>12:30-13:30</b> <i>Lunch Break</i></p> <p><b>13:30 - 15:30</b> <b>IVF PRACTICE</b><br/><i>Capsule:</i> Many practical issues are still unsettled<br/><i>Chairpersons:</i> <b>R. Frydman, France</b><br/><b>P.N. Barri, Spain</b><br/><b>Z. Ben-Rafael, Israel</b><br/><b>Expert opinion on controversial questions</b><br/><i>Discussants:</i> <b>S. Daya, Canada</b><br/><b>K. Diedrich, Germany</b><br/><b>Questions:</b></p> <ul style="list-style-type: none"> <li>• Natural cycles for IVF - to whom?</li> <li>• Starting dose of gonadotropins - low or regular?</li> <li>• Is there evidence to support the routine use of oral contraceptives in ART cycles?</li> <li>• ET technique - what matters?</li> </ul> |
|---|---|



## SCIENTIFIC PROGRAM

(CONTINUED)

Saturday, March 24, 2007

INFERTILITY & ART

HALL B

- Discussant:* **Y. Verlinsky, USA,**
- Questions:**
- ICSI for all patients?
  - Assisted zona hatching - what is the evidence?
  - Cytoplasmic transfer - is this procedure still performed?
  - Blastocysts vs. day 3 transfer
  - From stem cells to gamete – how feasible is it this procedure?
- Discussants:* **N. Gleicher, USA**  
**R.F. Casper, Canada**
- Questions:**
- Minimal monitoring of ovarian stimulation - is it safe?
  - Should we routinely support the luteal phase with Aspirin or Estradiol, or both?
  - Why did we stop performing ZIFT?
  - What is the best method for the prevention of multiple pregnancies?
- 
- 15:30-16:00** *Coffee Break*
- 
- 16:00-17:30** **SURGERY TO INCREASE IVF SUCCESS**
- Capsule:** *The dilemma with the following conditions is: Should we operate first, or operate only when IVF fails?*
- Chairpersons:* **J. Donnez, Belgium**  
**A.I. Ubeda, Spain**  
**Z. Shoham, Israel**
- 16:00-16:20** Resection of uterine septum or IVF - which comes first?  
**R. Labastida, Spain**
- 16:20-16:40** Myomectomy or art: which comes first?  
**Z. Ben-Rafael, Israel**
- 16:40-17:00** Endometrioma - should this be managed before IVF?  
**R. Frydman, France**
- 17:00-17:20** Cost effectiveness of salpingectomy prior to IVF - RCT  
**A. Strandell, Sweden**  
*Discussion*
- 17:30-19:00** **FREE COMMUNICATIONS**
- Chairpersons:* **A.I. Ubeda, Spain**  
**Z. Shoham, Israel**
- 17:30-17:40** Advancements made in reproductive medicine for human uterine transplants  
**E.R. Ramirez, USA**
- 17:40-17:50** Islam and gamete donation public perceptions of third party assisted conception in British Muslim communities  
**L. Culley, UK**
- 17:50-18:00** Thrombophilia and adverse pregnancy outcome  
**S. Fraga Marantes, Portugal**
- 18:00-18:10** Sildenafil decreased NK cell activity and promoted successful pregnancy in women with a history of RSA  
**M. Jerzak, Poland**
- 18:10-18:20** The effect of oral contraceptives on aromatase expression in the endometrium of myomatous uteri  
**H. Maia, Brazil**
- 18:20-18:30** Natural IVF cycle in poor responder patients  
**M. García- Yuste, Spain**
- 18:30-18:40** Chromosomal profiles of 1000 infertile males with non-obstructive sperm disorders  
**M. Ajina, Tunisia**
- 18:40-18:50** Binding capability of glycodelin on human sperm surface  
**G. Keck, Germany**





## SCIENTIFIC PROGRAM

(CONTINUED)

Saturday, March 24, 2007

FETO-MATERNAL MEDICINE

HALL C

### 08:30-10:00 INTRAUTERINE GROWTH RESTRICTION

**Capsule:** *What are the most appropriate strategies for preventing complications due to growth problems?*

#### Round Table Discussion

**Discussants:** **J. Gardosi, UK**  
**F. Figueras, Spain**

- Questions:**
- What are the perinatal effects of IUGR?
  - How should we screen for fetal growth problems?
  - How do we diagnose fetal growth restriction?
  - What investigations should be performed for decreased fetal movements?
  - When to deliver?

10:00-10:30 *Coffee Break*

### 10:30-12:30 RECURRENT PREGNANCY LOSS

**Capsule:** *Can we offer effective treatment for recurrent pregnancy loss despite the fact that the etiology is often unknown?*

**Chairpersons:** **D. Farine, Canada**  
**F. Chervenak, USA**  
**R. Buxaderas, Spain**

10:30-11:00 Second-trimester miscarriage – what do we know and what can be done?  
**R.B. Kalish, USA**

11:00-11:30 Advanced cervical dilatation with bulging membranes in mid-pregnancy: The role of emergency cerclage  
**U. Nicolini, Italy**

### 11:30-12:30 DEBATE Immunotherapy is inappropriate for treatment of recurrent pregnancy loss!

**Yes: R. Rai, UK**  
**No: O.B. Christiansen, Denmark**

12:30-13:30 *Lunch Break*

### 13:30-15:30 PREDICTION AND PREVENTION OF COMPLICATIONS

**Capsule:** *What can be done to predict and prevent complications during pregnancy?*

**Chairpersons:** **J. Gardosi, UK**  
**U. Nicolini, Italy**  
**R. Aurell, Spain**

13:30-14:00 Is the controversy on screening for gestational diabetes over?  
**D. Farin, Canada**

14:00-14:30 Can we predict or prevent pre-eclampsia?  
**K. Nicolaides, UK**

14:30-15:00 STAN monitor, pulse oximetry and cervicometry: "In" or "out"?  
**D. Farin, Canada**

15:00-15:30 Patient choice - cesarean: The role of evidence and ethics  
**F. Chervenak, USA**

15:30-16:00 *Coffee Break*

### 16:00-17:30 INTRAPARTUM SURVEILLANCE

**Capsule:** *Is it possible to minimize the risk of intrapartum asphyxia?*

#### Round Table Discussion

**Discussants:** **J. Gardosi, UK**  
**I. Ingemarsson, Sweden**

- Questions:**
- How do we assess 'fetal reserve'?
  - What is the evidence for intermittent vs. continuous monitoring?
  - Should admission tests be used? The case for and against
  - How do we assess acid base status?

### 17:30-19:00 FREE COMMUNICATIONS

**Chairperson:** **I. Ingemarsson, Sweden**  
**F. Figueras, Spain**  
**E. Sivan, Israel**

17:30-17:40 Primary repair of perineal tears. Thirty nine months follow up on 23 women  
**Y. Edden, Israel**

17:40-17:50 The controversies in intrahepatic cholestasis of pregnancy  
**P. Kascak, Slovakia**



## SCIENTIFIC PROGRAM

(CONTINUED)

### Saturday, March 24, 2007

#### FETO-MATERNAL MEDICINE

HALL C

- |   |   |
|---|---|
| <p><b>17:50-18:00</b> Audit of management of caesarean section in Glasgow<br/><b>A. Krishna, UK</b></p> <p><b>18:00-18:10</b> Role of hydrostatic balloon catheter in the management of major obstetric haemorrhage<br/><b>A. Krishna, UK</b></p> <p><b>18:10-18:20</b> The relationship between fetal biophysical profile and cord blood PH<br/><b>M. Valadan, Iran</b></p> <p><b>18:20-18:30</b> Management of cervical dilatation with bulging membranes in second trimester<br/><b>D. Tutunaru, Romania</b></p> | <p><b>18:30-18:40</b> Non-conventional approach to twin pregnancies complicated by extremely preterm premature rupture of membranes of one twin<br/><b>L. Keselman, Israel</b></p> <p><b>18:40-18:50</b> Prophylactic of immunological dysfunctions during pregnancy<br/><b>N.M. Pasma, Russia</b></p> <p><b>18:50-19:00</b> The effects of physiotherapeutic techniques on the prognostic of delivery and newborn<br/><b>M. De Conti, Brazil</b></p> |
|---|---|

### Sunday, March 25, 2007

#### GYNECOLOGY/ENDOSCOPY/MENOPAUSE AND FAMILY PLANNING

HALL A

- |  |   |
|--|---|
| <p><b>08:00-10:00</b> <b>GENITAL MALIGNANCIES</b><br/><i>Capsule: Are the new aggressive procedures coupled with better survival rates?</i><br/><i>Chairpersons: F. Nezhat, USA</i><br/><i>S. Dexeus, Spain</i><br/><i>L. Cabero-Roura, Spain</i></p> <p><b>08:00-08:30</b> "Intraperitoneal chemotherapy, is it worth it?"<br/><b>R.G. Moore, USA</b></p> | <p><b>08:30-09:00</b> Conservative treatment of ovarian carcinoma<br/><b>S. Dexeus, Spain</b></p> <p><b>09:00-09:30</b> Should low malignant potential tumors be surgically staged?<br/><b>R.G. Moore, USA</b></p> <p><b>09:30-10:00</b> Role of laparoscopy in ovarian cancer?<br/><b>F. Nezhat, USA</b></p> <p><b>10:00-10:30</b> <i>Coffee Break</i></p> |
|--|---|

#### INFERTILITY & ART

HALL B

- |  |   |
|--|---|
| <p><b>08:00-10:00</b> <b>GAMETE AND OVARIAN CRYOPRESERVATION</b><br/><i>Capsule: Newer cryopreservation techniques – promising clinical or research tools?</i><br/><i>Chairpersons: N. Gleicher, USA</i><br/><i>Y. Gonen, Israel</i><br/><i>B. Martinez-Madrid, Spain</i></p> <p><b>08:00-08:30</b> When should we cryopreserve testicular tissue?<br/><b>H. Tournaye, Belgium</b></p> <p><b>08:30-09:00</b> Ovarian transplantation in the pelvic organs - is it in the clinical or research stage?<br/><b>J. Donnez, Belgium</b><br/><b>Ovulation Induction: A New Player on the Block</b></p> | <p><b>09:00-10:00</b> <b>DEBATE</b><br/><b>Aromatase inhibitor, Letrozole, shows promising results in infertility treatment. Are we sure of the evidence? Do we know the risks?</b><br/><b>Yes:</b> Aromatase inhibitors are efficient and safe!<br/><b>R.F. Casper, Canada</b><br/><b>No:</b> Aromatase inhibitors - the risk is too high, the evidence is not there!<br/><b>S. Daya, Canada</b></p> <p><b>10:00-10:30</b> <i>Coffee Break</i></p> |
|--|---|



## SCIENTIFIC PROGRAM

(CONTINUED)

Sunday, March 25, 2007

### INFERTILITY & ART

HALL B

**10:30-12:30** **ENDOMETRIOSIS**

**Capsule:** *Can we choose between the many options of therapy for this poorly understood condition?*

**Chairpersons:** **Z. Shoham, Israel**  
**J. Garcia-Velasco, Spain**  
**E. Zupi, Italy**

**10:30-11:00** Genetic basis of endometriosis: Was Sampson right?  
**R.F. Casper, Canada**

**11:00-11:30** Endometriosis – surgery or IVF?  
**P.N. Barri, Spain**

**11:30-12:00** Endometriosis and pelvic pains - surgery or medical treatment?  
**E. Zupi, Italy**

**12:00-12:30** Endometriomas - stripping or coagulation?  
**M. Vignali, Italy**

### FETO-MATERNAL MEDICINE

HALL C

**08:00-10:00** **SEVERE ANTEPARTUM AND INTRAPARTUM BLEEDING**

**Capsule:** *Severe bleeding during pregnancy and post-delivery still represents a challenge even for the experienced physician*

**Chairpersons:** **F. Chervenak, USA**  
**I. Blickstein, Israel**  
**D. Dexeus, Spain**

**08:00-08:30** Can we reduce the risks of abnormal placentation (previa and accreta): Antepartum and intrapartum considerations?  
**S. Chasen, USA**

**08:30-09:00** Consumption coagulopathy: More than just blood replacement?  
**D. Blickstein, Israel**

**09:00-09:30** Uterine atony: What can be done before hysterectomy?  
**B. Serra, Spain**

**09:30-10:00** Is it possible to prevent neurological morbidity in the preterm baby?  
**G.C. Di Renzo, Italy**

**10:00-10:30** *Coffee Break*

**10:30-12:30** **DELIVERY PRACTICE**

**Capsule:** *Do we have new answers to these old problems?*

**Chairpersons:** **G.C. Di Renzo, Italy**  
**M. Hallak, Israel**  
**R. Aurell, Spain**

**10:30-11:00** Multiple pregnancy prevention in ART  
**R. Aurell, Spain**

**11:00-11:30** Postdate: When and how to induce?  
**F. Facchinetti, Italy**

**11:30-12:00** Elective preterm delivery in monochorionic twins  
**I. Blickstein, Israel**

**12:00-12:30** The end of forceps and vacuum?  
**A. Grunebaum, USA**

